EUVIMEDEUVIMED entdecken
Open Access

Successfully Navigating Food and Drug Administration Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The National Institutes of Health Platform Vector Gene Therapy Experience

Richa Madan Lomash iD, Oleg Shchelochkov, Randy J Chandler, Charles P Venditti iD, Anne R Pariser, Elizabeth A Ottinger, NIH PaVe-GT Team

Human Gene Therapy · 2023

DOI: 10.1089/hum.2022.232 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, 2023. Verfasst von Richa Madan Lomash und 6 weiteren Autor:innen. Beteiligte Einrichtung: Therapeutic Development Branch, Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), NIH, Rockville, Mar…. Hauptthemen laut MEDLINE: Orphan Drug Production, Propionic Acidemia. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Intramural NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Orphan Drug ProductionPropionic AcidemiaHumansUnited StatesChildUnited States Food and Drug AdministrationDrug ApprovalRare DiseasesGenetic TherapyNational Institutes of Health (U.S.)

Stichwörter der Autor:innen

Rare Pediatric Disease Designationfinancial incentivesgene therapyorphan drugorphan drug designationrare diseases

Autor:innen und Institutionen

  • Therapeutic Development Branch, Division of Preclinical Innovation, National Center for Advancing Translational Sciences (NCATS), NIH, Rockville, Maryland, USA.
  • Organic Acid Research Section, Molecular Medicine Branch, National Human Genome Research Institute (NHGRI), NIH, Bethesda, Maryland, USA.
  • Division of Rare Diseases Research Innovation, NCATS, NIH, Rockville, Maryland, USA.

ORCID-Profile: Richa Madan Lomash, Charles P Venditti

Förderung

  • Intramural NIH HHS

Zitieren

APA

Lomash, R. M., Shchelochkov, O., Chandler, R. J., Venditti, C. P., Pariser, A. R., Ottinger, E. A., & NIH PaVe-GT Team (2023). Successfully Navigating Food and Drug Administration Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The National Institutes of Health Platform Vector Gene Therapy Experience. Human Gene Therapy. https://doi.org/10.1089/hum.2022.232

Vancouver

Lomash RM, Shchelochkov O, Chandler RJ, Venditti CP, Pariser AR, Ottinger EA, et al. Successfully Navigating Food and Drug Administration Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The National Institutes of Health Platform Vector Gene Therapy Experience. Human Gene Therapy. 2023. doi:10.1089/hum.2022.232

BibTeX
@article{Lomash2023,
  author = {Lomash, Richa Madan and Shchelochkov, Oleg and Chandler, Randy J and Venditti, Charles P and Pariser, Anne R and Ottinger, Elizabeth A and NIH PaVe-GT Team, NIH PaVe-GT Team},
  title = {Successfully Navigating Food and Drug Administration Orphan Drug and Rare Pediatric Disease Designations for AAV9-hPCCA Gene Therapy: The National Institutes of Health Platform Vector Gene Therapy Experience},
  journal = {Human Gene Therapy},
  year = {2023},
  doi = {10.1089/hum.2022.232}
}
Kostenlos starten →